By Karen Roman Waldencast plc (Nasdaq: WALD) said fourth quarter net revenue grew 30.8% to $72.1 million. Adjusted EBITDA doubled from the year prior to $11.2 million, or 15.5% of net revenue, driven by top-line performance and operational leverage, the...

By Daniella Parra Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up to $740 million. Araris’ AraLinQ platform enhances ADC drug design,...

By Exec Edge Editorial Staff The fast-growing sector of iGaming has its share of success stories, but few can match the rocket-like trajectory of SPRIBE under David Natroshvili’s leadership. We sat down with the founder and CEO to discuss SPRIBE’s...

By Exec Edge Editorial Staff As the CEO of Hometown, a leading digital platform for K-12 schools and universities, Nick Mirisis has transformed what began as a ticketing service into a comprehensive solution for educational institutions across the United States....

By Jarrett Banks AirSculpt, which provides body contouring procedures, said it was implementing an operating plan after a challenging 2024. “We are developing the right operating plan and implementing the right actions to improve our platform and progress toward positive...

By Karen Roman HF Foods Group Inc. (Nasdaq: HFFG) said fourth quarter net revenue increased 8.7% to $305.3 million compared to $280.9 million in the year prior. Quarterly adjusted EBITDA rose 39.4% to $14.5 million in comparison to $10.4 million,...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) implant, in the first-in-human clinical trial of its kind. The company also said it achieved full enrollment for this study, which targets...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said it expects to spin off Cortigent, Inc., its brain implant devices division, as an independent publicly-traded company. Vivani aims to create two companies focused on driving long term value creation in...

By Karen Roman Grove Collaborative Holdings, Inc. (NYSE: GROV) said annual adjusted EBITDA was $1.3 million, increasing $10.5 million year-over-year. Operating cash flow for Q4 was $0.3 million, making it the third consecutive quarter with positive results, it said. Grove...

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had...